Earnings Call · Q4 FY2022·2023-03-10

Q4 22EPS -2.04%·Rev n/aQ3 22EPS +18.03%·Rev n/aQ2 22EPS -25.76%·Rev n/aQ1 22EPS -1.59%·Rev n/a⚠ consensus missing

Fulcrum Therapeutics, Inc. FULC

Chris Calabrese — Investor Relations

Robert Gould — Chief Executive Officer

Esther Rajavelu — Chief Financial Officer

−23.0%1d on move date−21.2% vs SPY3d−28.1%5d−39.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more FULC calls or request research access.

More FULC calls Browse calls Request research access